La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BlackSky Technology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BlackSky Technology..

BlackSky Technology (NYSE:BKSY) Azioni, Catena delle Opzioni

BlackSky Technology

BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and from other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BlackSky Technology Inc. Class A Common Stock

BKSY

HYZN

MTRX

ORCL

Scopri i 5 titoli da seguire oggi, 9 settembre 2024, con Oracle, BlackSky, Mission Produce e altri nel mirino.

Pre-market: 5 titoli da monitorare oggi, 9 settembre 2024

BlackSky Technology Inc

BlackSky Technology Inc. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock

Baird analyst Joel Beatty maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and raises the price target from $52 to $70.

Price Target

Analyst Ratings

PTCT

Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $70

HIGHLIGHTS
(All financial figures are unaudited and in Canadian dollars unless otherwise noted. &#x2A; identifies non-GAAP financial measures. See the Non-GAAP and Other Financial Measures section of this news release)
<ul>
<li>Announced 2025 adjusted earnings before interest, income taxes and depreciation (EBITDA)&#x2A; guidance of $19.4 billion to $20.0 billion and distributable cash flow (DCF)&#x2A; per share of $5.50 to $5.90</li>
<li>Declared 30th consecutive annual common share dividend increase, raising it by 3.0% to $0.9425 per quarter ($3.77 annualized), effective March 1, 2025</li>
<li>Reaffirmed 2024 full year guidance for EBITDA and DCF per share; the Company expects to finish the year near the top end of the EBITDA range of $17.7 billion to $18.3 billion, and around the midpoint for DCF per share</li>
<li>The Company reaffirmed its 2023 to 2026 growth outlook of 7-9% for EBITDA&#x2A; growth, 4-6% for adjusted earnings per share (EPS)&#x2A; growth and approximately 3% for DCF per share&#x2A; growth</li>
</ul>

Guidance

Enbridge Reaffirms 2024 Guidance; For 2025 Sees Adjusted EBITDA Of $19.4B-$20B And DCF Per Share Of $5.50-$5.90

Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $45 to $56.

Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $56

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) struggle to cross the $100,000 mark is due to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42270361/why-bitcoins-institutionalization-is-a-concern">profit-taking, derivatives data and historical trends</a>, analysts tell Benzinga.
Bitcoin is currently trading at $94,870, down 0.4% for the day, according to <a href="https://www.coingecko.com/en/coins/bitcoin">data</a> from CoinGecko.
Avinash Shekhar, co-founder and CEO of Pi42, told Benzinga that Bitcoin's pullback reflects a consolidation phase rather than weakness. 
He highlighted the robust demand in derivatives markets, with traders paying a 17% annualized premium for leveraged BTC positions. 
"The Bitcoin options markets also show confidence, as options are trading at an 8% discount, indicating reduced hedging demand," Shekhar said. 
He added that funding rates for perpetual contracts remain neutral at 1.4%, supporting a balanced leverage environment.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42275232/leveraged-microstrategy-etfs-are-playing-with-fire-experts-warn">Leveraged MicroStrategy ETFs Are Playing With Fire, Experts Warn</a>
James Toledano, COO of Unity Wallet, attributes Bitcoin's dip to profit-taking following its $25,000 surge in the past month. 
He noted that the presence of put options between $98,000 and $99,000 has created resistance levels. 
"Profit-taking has likely exerted downward pressure on the price," Toledano told Benzinga, cautioning that Bitcoin's historical patterns show significant corrections after rapid ascents. 
He cited previous cycles, such as 2017 and 2021, where Bitcoin's steep gains were followed by sharp declines of up to 70%.
Arthur Azizov, CEO of B2BINPAY, observed that Bitcoin has been trading within a tight range of $91,000 to $99,000, with the $100,000 mark acting as a psychological barrier. 
Speaking with Benzinga, Azizov predicted a potential pullback to $82,000 but noted that interest in the market remains strong, driven by altcoin season and substantial inflows from institutional and retail investors. 
According to CoinMarketCap's Alt season Index, the market is in alt season territory, with a score of 83.
Technical analysts at Fairlead Strategies maintain a neutral short-term outlook for Bitcoin, citing indicators such as the daily MACD and DeMARK signals that point to consolidation. 
They identified $80,400 as the initial support level and $100,000 as key resistance. Long-term momentum, however, remains strong, supporting a bullish outlook beyond the current consolidation phase.
"All signs hint at Bitcoin being in its consolidation phase rather than a weakness phase," Shekhar further said.
Toledano echoed this sentiment, cautioning that while corrections are common after rapid gains, they don't necessarily signal the end of <a href="https://www.benzinga.com/money/bitcoin-price-prediction">Bitcoin's bull run</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42273301/joe-biden-pardons-hunter-donald-trump-likely-to-pardon-january-6-protestors-polymarket-traders-speculate">Joe Biden Pardons Hunter — Donald Trump Likely To Pardon January 6 Protestors, Polymarket Traders Speculate</a></li>
</ul>
Image: Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

EXCLUSIVE: Why Bitcoin Cannot Crack $100,000 Just Yet

Barclays analyst Thomas O'Malley maintains Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with a Overweight and raises the price target from $32 to $80.

CRDO

Barclays Maintains Overweight on Credo Technology Group, Raises Price Target to $80

ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "Company or "ParaZero"), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircrafts, announced the successful delivery of a special drone safety system project for a leading Fortune 500 automotive manufacturer ("the Customer") as part of the Customer's proprietary drone program.
The project included the design, development and delivery of a custom ParaZero SafeAir&#x2122; system specifically engineered to meet exceptionally demanding flight conditions and specifications unique to the Customer's proprietary aircraft program. This initiative commenced at the design stage, ensuring optimized and seamless integration of the safety system onto the aircraft and addressing its unique flight envelope and operational characteristics. This delivery highlights ParaZero's ability to provide advanced safety solutions for diverse aerial platforms, including multirotor, single rotor, fixed-wing, VTOL, manned and unmanned vehicles, and urban air mobility aircraft.
The successful execution of this project further highlights ParaZero's reputation for developing custom product variants tailored to meet the stringent requirements and standards of aircraft across various industries. It also serves as a testament to the long-standing relationship between ParaZero and the Customer, which spans multiple successful collaborations. In late 2023, ParaZero received its second purchase order from the Customer, reinforcing this ongoing partnership.

PRZO

ParaZero Delivers Custom Drone Safety System To Leading Automotive Manufacturer Client

Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported plans to launch a foldable iPhone in 2026 could breathe new life into the foldable smartphone market, which has been experiencing waning consumer interest.
What Happened: Display analyst Ross Young has indicated that Apple aims to enter the foldable market in the latter half of 2026. This strategic move could significantly boost the market, with projections of a record-breaking year.
Young anticipates a growth of over 30% in&nbsp;the foldable market in 2026,&nbsp;followed by a 20%&nbsp;growth in 2027 and 2028.
See Also: <a href="https://www.benzinga.com/news/legal/24/12/42283614/apple-faces-lawsuit-over-alleged-snooping-on-employees-iphones-and-other-devices">Apple Faces Lawsuit Over Alleged Snooping On Employees&#8217; iPhones And Other Devices</a>
Speculation has been rife about Apple&#8217;s foldable iPhone, with analysts predicting a launch around September 2026. The device is expected to feature a size range&nbsp;between 7.9 and 8.3 inches, adopting a &#8220;clamshell&#8221; design akin to Samsung&#8217;s Galaxy Z Flip.
This approach would allow the iPhone to fold vertically, offering a full-size device when opened and a compact form when closed.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The introduction of a foldable iPhone by Apple comes after eight generations of foldable phones from competitors like Samsung. According to a <a href="https://www.benzinga.com/news/24/02/37205827/apples-foldable-iphone-to-launch-in-2026-eight-generations-after-samsungs-first-foldable-phone-repor">report</a> by the Korean publication Alpha Economy, Apple has set September 2026 as the launch date for its foldable iPhone, marking a significant milestone in the company&#8217;s product lineup.
Meanwhile, the global smartphone market is poised for a rebound. According to&nbsp;<a href="https://www.benzinga.com/24/11/42209622/apple-faces-modest-growth-as-idc-forecasts-smartphone-market-rebound">International Data Corporation</a>, global smartphone shipments are expected to rise by 6.2% year-over-year in 2024, reaching 1.24 billion units.
This growth follows two years of decline, driven by pent-up demand for device upgrades. However, growth is expected to slow to low single digits from 2025 onward.
To make things difficult for Apple, Chinese tech giant&nbsp;Huawei Technologies Co.&nbsp;has been <a href="https://www.benzinga.com/news/24/09/40845772/huaweis-2-800-tri-fold-phone-has-the-potential-to-eat-apples-lunch-in-china-here-is-how-it-compares">ramping up efforts to challenge</a> the iPhone maker's dominance. The Chinese smartphone maker recently launched the Mate XT, a tri-fold phone priced at $2,800, significantly higher than Apple&#8217;s iPhone 16 Pro Max.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42253830/elon-musk-agrees-with-steve-jobs-on-the-most-important-job-of-a-ceo-heres-what-the-legendary-apple-co-founder-had-to-say">Elon Musk Agrees With Steve Jobs On The Most Important Job Of A CEO</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Tech

AAPL

Apple's Foldable iPhone Could Spark Smartphone Market Revival In 2026, Says Expert

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent &amp; Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.&nbsp;

BCLI

BrainStorm Receives Notice Of Allowance fFr U.S. Patent On Innovative Exosome Platform Technology

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Reiteration

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Biotech

Health Care

General

CRBP

The FDA Has Granted Fast Track Designation To Corbus Pharmaceuticals' CRB-701 For Relapsed Or Refractory Metastatic Cervical Cancer

JP Morgan analyst Brian Ossenbeck maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Overweight and raises the price target from $350 to $366.

JP Morgan Maintains Overweight on FedEx, Raises Price Target to $366

GILD

Gilead And Tubulis Enter Exclusive Option And License Agreement to Develop ADC Candidate For Select Solid Tumor Target; Tubulis To Receive $20M Upfront Payment And A Separate Option Exercise Fee Of $30M If Gilead Exercises Its Option, Tubilis Will Also Be Eligible For Up To $415M In Milestones Plus Royalties On Sales

<ul>
<li>Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels</li>
<li>Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts</li>
<li>High levels of target coverage achieved with once daily dosing at all doses</li>
<li>Completion of dose escalation and initiation of dose expansion expected in 1H25</li>
<li>Additional efficacy data expected in 4Q25, including longer term major molecular response (MMR) rates</li>
</ul>

TERN

Terns Pharmaceuticals Announced Early Data From The Ongoing Dose Escalation Part Of The Phase 1 CARDINAL Study Evaluating TERN-701 In Patients With Relapsed/Refractory Chronic Myeloid Leukemia

Enbridge Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) (Enbridge or the Company) announced today that its Board of Directors has declared a quarterly dividend of C$0.9425 per common share, payable on March 1, 2025 to shareholders of record on February 14, 2025.&nbsp; The declared dividend represents a 3% increase from the prior quarterly rate and the thirtieth consecutive year in which the Company has increased its common share dividend.

Dividends

TSX:ENB

Enbridge Increases Quarterly Dividend By 3% To C$0.9425/Common Share, Payable March 1, 2025

<ul>
<li>This includes an upfront payment of $483.4 million, to be adjusted for inventory at close, and $75.0 million in potential net sales milestone payments. Coherus plans to use a portion of the transaction proceeds to fully repay the entirety of the Company's $230.0 million in existing convertible notes due April 2026 and $49.1 million to buy-out certain royalty obligations related to UDENYCA.</li>
<li>Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor.</li>
<li>Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody.</li>
<li>Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026</li>
</ul>

CHRS

Coherus Biosciences Has Agreed To Divest Udenyca (Pegfilgrastim) Franchise To Intas Pharmaceuticals For Up To $558.4M

U.S. stock futures were in negative territory during Tuesday&#8217;s premarket hours as the dollar slipped to 106.3 level.
The U.S. 10-year and two-year Treasury notes yielded 4.21% and 4.18%, respectively. Expectations of a further 25 basis point rate cut in December rose to 72.5%, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.02%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Russel 2000</td>
<td>-0.11%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.01% to $603.60 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.09% to $514.84, according to <a href="https://www.benzinga.com/">Benzinga Pro</a> data.
Cues From The Last Session
The U.S. stock market closed higher on Monday, with the <a href="https://www.benzinga.com/24/12/42282669/sp-nasdaq-settle-at-record-highs-as-tesla-shares-surge-investor-sentiment-decreases-but-fear-greed-index-remains-in-greed-zone">S&amp;P 500 and Nasdaq Composite reaching new highs</a>.
Key Drivers:
<ul>
<li>Tesla Boost: Tesla shares surged 3.5% after Roth MKM upgraded the stock and raised its price target.</li>
<li>Super Micro Rebound: Super Micro Computer stock jumped 29% following a positive company announcement.</li>
<li>Economic Data: U.S. construction spending increased and the ISM manufacturing PMI rose, beating expectations.</li>
<li>Sector Performance: While most S&amp;P 500 sectors closed lower, communication services and consumer discretionary stocks outperformed. Utilities, real estate, and financials lagged.</li>
</ul>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.97%</td>
<td>19,404</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.24%</td>
<td>6,047.15</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.29%</td>
<td>44,782</td>
</tr>
<tr>
<td>Russel 2000</td>
<td>-0.02</td>
<td>2,434</td>
</tr>
</tbody>
</table>
</figure>
Also read: <a href="https://www.benzinga.com/markets/equities/24/12/42282948/ubs-forecasts-sp-500-to-hit-6600-in-2025-citing-support-from-over-easy-global-central-bank-policy">UBS Forecasts S&amp;P 500 To Hit 6,600 In 2025, Citing Support From &#8216;Over-Easy Global Central Bank Policy&#8217;</a>
Insights From Analysts: Chief investment officer at UBS Global Wealth Management, Mark Haefele termed the decade so far as the &#8220;Roaring 20s,&#8221; marked by high economic growth, strong market returns, and improving productivity.
In his ‘<a href="https://www.ubs.com/global/en/wealthmanagement/insights/chief-investment-office/roaring-20s-the-next-stage.html#review">UBS Year Ahead 2025 Report</a>‘ he said "After strong years for equities in 2023 and 2024, we see further upside in 2025. We expect the S&amp;P 500 to reach 6,600 by the end of 2025, around 10% higher than today&#8217;s levels."
"We expect central banks to cut interest rates further in the year ahead, reducing cash returns," Haefele added.
Highlighting his economic outlook he said, "In our base case, we expect sustained economic growth in the U.S., supported by healthy consumption, loose fiscal policy, and lower interest rates. Tariff threats are a headwind for Asia and Europe. If imposed, they could be partially offset by reactive stimulus measures in China."
Chief market strategist at Carson Group LLC, Ryan Detrick highlighted that &#8220;With a new high in December, we&#8217;ve seen new highs in 10 out of 12 months this year (April and August didn&#8217;t).&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today was the 54th all-time high in &#39;24 for the S&amp;P 500. Officially the 5th most ever (since 1957 when it moved to 500 stocks). 62 in 2017 is next up. With a new high in December, we&#39;ve seen new highs in 10 out of 12 months this year (April and August didn&#39;t). Not bad. <a href="https://t.co/FiEJ27kjVr">pic.twitter.com/FiEJ27kjVr</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1863771861034668045?ref_src=twsrc%5Etfw">December 3, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Unrelated to past cycles, global central banks are easing monetary policy despite strong economic growth, high asset prices, and elevated inflation, said Bob Elliott, the chief investment officer at Unlimited Funds. Elliott presented the underlying data reiterating these conditions in a thread on X, indicating a positive sign for the markets.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The global economy is getting a shot of adrenaline from a coordinated central bank easing. But unlike the past, it comes at a time when growth is pretty good, asset prices are near highs, and inflation remains elevated. Thread.
&mdash; Bob Elliott (@BobEUnlimited) <a href="https://twitter.com/BobEUnlimited/status/1863551595545334237?ref_src=twsrc%5Etfw">December 2, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data
This week&#8217;s economic calendar is packed after a short last week due to Thanksgiving.
<ul>
<li>On Tuesday, job openings data for October will be released at 10:00 a.m. ET and auto sales data will be released for which the time is yet to be determined.</li>
<li>On Wednesday, November&#8217;s data on ADP employment will be released at 8:15 a.m. ET.</li>
<li>St. Louis Fed President Musalem will speak at 8:45 a.m. ET.</li>
<li>The S&amp;P final U.S. services PMI for November will be released at 9:45 a.m. ET.</li>
<li>The ISM services and factory orders data for November and October, respectively, will be released at 10:00 a.m. ET.</li>
<li>Fed Beige Book will be released at 2:00 p.m. ET.</li>
<li>On Thursday, initial jobless claims data for November and U.S. trade deficit data for October will be released at 8:30 a.m. ET.</li>
<li>On Friday, the U.S. employment report, U.S. unemployment rate, and U.S. hourly wages data will be released at 8:30 a.m. ET.</li>
<li>The preliminary data for consumer sentiment will be released at 10 a.m. ET.</li>
<li>Chicago Fed President Goolsbee will speak at 10:30 a.m., ET.</li>
<li>Consumer credit data will be released at 3:00 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Shimmick Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) was 57.5% higher at $4.43 apiece in premarket after it landed a $45.4 million contract to build the Murray Street Bridge in Santa Cruz.</li>
<li>Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)<a href="https://www.benzinga.com/24/12/42284776/super-micro-shares-rise-over-7-in-premarket-after-independent-special-committee-found-no-evidence-of-misconduct-but-top-investment-bank-flags-two-key-points-to-watch"> was 6.67% up</a> at $44.8 per share after it announced that the independent Special Committee formed by the company&#8217;s board completed its review.</li>
<li>Santi Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares were 4.50% down at $9.55 apiece after it secured a $37.6 million private placement financing through the sale of 16,713 shares of Series A Convertible Preferred Stock.</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares were down 1.3% to $352.44 apiece after Elon Musk&#8217;s pay package was rejected again by a Delaware judge despite being approved by Tesla shareholders at a June meeting.</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) was up 0.17% at $23.97 per share after the retirement announcement of its chief executive officer, Pat Gelsinger.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.91% to hover around $68.72.
The Dollar Index was down 0.12% to 106.3 level. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was down 0.16% over the past 24 hours and traded just over the $95K mark.
Major Asian markets closed higher on Tuesday. European markets were also upbeat. 
<ul>
<li>Read next: <a href="https://www.benzinga.com/24/12/42283257/charles-schwab-goldman-sachs-invesco-add-mara-holdings-morgan-stanley-cuts-stake-here-is-what-changed-with-mara-holdings-in-q3">Charles Schwab, Goldman Sachs Boosts MARA Stake As Stock Rallies 30% In Past 6 Months: Morgan Stanley, Other Major Funds Trim Positions In Q3</a></li>
</ul>
Image via Shutterstock

Equities

INTC

SHIM

SMCI

SNTI

TSLA

US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&P Hits 54th All-Time High This Year: Analyst Sees 'Further Upside' Of Around 10% In 2025 From Current Levels

Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced an exclusive global development and commercialization license agreement with Takeda (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) to advance elritercept. Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome ("MDS") and one in patients with myelofibrosis ("MF"). The Phase 3 RENEW clinical trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS will begin enrollment soon.
Under the terms of the agreement, Takeda will obtain an exclusive license to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Subject to the terms of the agreement, Keros will receive a $200 million upfront cash payment and is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.

KROS

Takeda Tapped Keros Therapeutics Under A $200M Deal Along With Earn Out Of Over $1.1B To Boost Oncology Pipeline with Elritercept Beyond China, Hong Kong and Macau

ONCY

Oncolytics Biotech Completes Initial Safety Phase Enrollment For GOBLET Trial's Pancreatic Cancer Cohort

Jefferies analyst Brent Thill maintains DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Buy and raises the price target from $80 to $95.

DOCU

Jefferies Maintains Buy on DocuSign, Raises Price Target to $95

ROIV

Roivant Says Its Subsidiary Kinevant Sciences' Phase 2 RESOLVE-Lung Study Of Namilumab For Chronic Active Pulmonary Sarcoidosis Failed To Meet The Primary Endpoint, Further Development Of Namilumab For Sarcoidosis Will Be Discontinued

Reports Q3 revenue $22.5M, consensus $27.48M."We delivered a strong quarter of multi-year contract bookings valued up to $780 million, continuing t...

BlackSky reports Q3 EPS (66c), consensus (65c)

BlackSky (BKSY) is starting to ramp up revenues from recent contract awards and continues to work on a number of sizable new and expansion contract...

BlackSky sees FY24 revenue $102M- $118M, consensus $108.13M

In a report released today, Jeff Van Rhee from Craig-Hallum maintained a Buy rating on BlackSky Technology (BKSY – Research Report). The company's ...

BlackSky Technology (BKSY) Gets a Buy from Craig-Hallum

Blacksky Technology Inc. (BKSY) Q3 2024 Earnings Call Transcript

Blacksky Technology Inc. ( ($BKSY) ) has released its Q3 earnings. Here is a breakdown of the information Blacksky Technology Inc. presented to its...

BlackSky Technology Reports Q3 Growth and Strategic Wins

Oppenheimer analyst Timothy Horan maintained a Buy rating on BlackSky Technology (BKSY – Research Report) today and set a price target of $10.00. T...

Oppenheimer Reaffirms Their Buy Rating on BlackSky Technology (BKSY)

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Ceva (CEVA – Research Report) and BlackSky Technolog...

Analysts Offer Insights on Technology Companies: Ceva (CEVA) and BlackSky Technology (BKSY)

BlackSky (BKSY) is up 21.2%, or $1.57 to $8.97. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

BlackSky rises 21.2%

BlackSky: Next-Gen Satellites Bring Opportunities And Risks

BlackSky (BKSY) is up 5.9%, or 65c to $11.60. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

BlackSky rises 5.9%

CEVA

Press Releases

BlackSky Announces Pricing of Upsized $40 Million Public Offering of Common Stock

Penny Stocks

BlackSky Wins U.S. Navy Research Contract for Gen-3 Advanced Optical Intersatellite Links

BlackSky Announces Closing of Public Offering of Common Stock

BlackSky Wins Approximately $6 Million Contract Expansion with Legacy International Defense Sector Customer for Assured, High-Frequency Satellite Imagery Services

BlackSky Wins Five-Year NGA Luno A Contract Valued Up to $290 Million to Monitor Global Economic Activity and Military Capability

BlackSky Wins Seven-Figure Contract for Advanced Space Domain Awareness Solutions

BlackSky to Host Third Quarter 2024 Results Conference Call

LeoStella and BlackSky Selected for Space Development Agency Hybrid Acquisition for Proliferated Low-Earth Orbit program

BlackSky Reports Third Quarter 2024 Results

BlackSky to Participate at Three Upcoming Investor Conferences

Aeries Technology, Inc. - Class A Ordinary Share

Aeries Technology

Amentum Holdings

CBIZ

CRA Intl

Sunrise New Energy Co., Ltd - Class A Ordinary Shares

Sunrise New Energy

Falcon's Beyond Global, Inc. - Class A Common Stock

Falcons Beyond Global

Franklin Covey

Forrester Res

Graphex Group Limited American Depositary Shares, each American Depositary Share representing 20 Ordinary Shares

Graphex Gr

Huron Consulting Group Inc. - Common Stock

Huron Consulting Gr

ICF International

Innodata

Lichen China Limited - Class A Ordinary Shares

Lichen China

LegalZoom.com

MISTRAS Group

FiscalNote Holdings, Inc. Class A common stock

FiscalNote Holdings

NV5 Global

Planet Labs

RCM Technologies

Resources Connection, Inc. - Common Stock

Resources Connection

SOS Limited American Depositary Shares, one hundred and fifty (150) Class A Ordinary Shares

Comments

BlackSky Technology

BlackSky Technology (BKSY) Opzioni

BlackSky Technology (NYSE:BKSY) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO